Recruiting × Uterine Cervical Neoplasms × Gynecologic × Clear all Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Phase 1 Recruiting
40 enrolled
SHIP-A-S01
Phase NA Recruiting
750 enrolled
Comparison Between Liquid-Based Cytology And Molecular Screening For Detecting Precursor Lesions and Cervical Cancer
Phase NA Recruiting
558 enrolled
Keynote B59
Phase 1/2 Recruiting
317 enrolled
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Recruiting
105 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
Phase 2/3 Recruiting
120 enrolled
TroFuse-020
Phase 3 Recruiting
686 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
PROPS GYN
Phase 2 Recruiting
25 enrolled
ELEPHAS-04
Recruiting
324 enrolled
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Phase 4 Recruiting
100 enrolled
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 Recruiting
24 enrolled
POC
Phase NA Recruiting
5,000 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
AIM-C1
Phase NA Recruiting
40 enrolled
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1 Recruiting
110 enrolled
A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2 Recruiting
100 enrolled
Cervical Cancer Detection Using Optical Spectroscopy
Phase NA Recruiting
350 enrolled
Calla
Phase NA Recruiting
305 enrolled
Embrace Gyn
Phase NA Recruiting
70 enrolled
HPVDNA02
Phase NA Recruiting
64 enrolled
NeCTuR
Recruiting
750 enrolled
Detecting HPV DNA in Anal and Cervical Cancers
Recruiting
20 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
Ameliorated Pap Tests and Cervical Cancer Screening Participation
Phase NA Recruiting
248 enrolled
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Phase NA Recruiting
400 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
Thermal Artifact in Patients Undergoing Conization: A Clinical Study
Phase NA Recruiting
150 enrolled
Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study
Recruiting
300 enrolled
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1/2 Recruiting
15 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
CASCADE3001A
Phase NA Recruiting
1,600 enrolled
INTLECTUAL
Phase 2 Recruiting
17 enrolled
DEHIM_CCRT
Phase 2 Recruiting
34 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
PAROLA
Phase 3 Recruiting
510 enrolled
(iSTAR)
Phase NA Recruiting
600 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled
DP-04
Recruiting
100 enrolled
RIFT-HPV
Phase 4 Recruiting
69 enrolled
ASHA-Health II
Phase NA Recruiting
420 enrolled
Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer
Recruiting
1,800 enrolled
Spatially Fractionated Radiation Treatment for Gynaecological Cancers
Phase NA Recruiting
20 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
RAPPAL
Phase NA Recruiting
230 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled